TCON traconpharma.com: Company Value to Revenue

Public company logo of TRACON Pharmaceuticals Inc. (TCON)

Does TRACON Pharmaceuticals (TCON) have a future after a competitor went bankrupt due to failed trials? The Enterprise Value-to-revenue ratio provides the answer: biomaterial logistics efficiency supports profitability, while the magnitude of characterizes this valuation level. Ultimately, TRACON Pharmaceuticals (TCON) is creating a unique tumor-fighting pipeline, establishing a vital medical ecosystem.

TCON TRACON Pharmaceuticals EV/Sales Multiple (07/04/2022 - 11/20/2026)

Financial and market metric breakdowns for TRACON Pharmaceuticals Inc. (TCON)

- company stock capitalization data:
Fundamental valuation:TRACON Pharmaceuticals (TCON)
Core merchandise of TRACON Pharmaceuticals, Inc.

This metric measures the total enterprise value minus net debt per unit of revenue, determining the market revaluation of operating income excluding financial leverage. An analysis of the market value-to-revenue ratio for TRACON Pharmaceuticals (TCON) confirms an asset-light model due to the outsourcing of synthesis and testing to third-party contractors, which makes the capitalization dependent on R&D success rather than production capacities.

Competitor analysis for TRACON Pharmaceuticals

TEM (tempus.com) - Company Value to Revenue Ratio|qiagen.com (QGEN) - Enterprise Value-to-Revenue Ratio|Ionis (IONS) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Repligen|Avidity (RNA) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple CRSP|Total Company Value-to-Revenue Ratio GeneDx|Enterprise Value-to-Revenue Ratio Ultragenyx RARE|Total Company Value-to-Revenue Ratio Beam Therapeutics (BEAM)|SRPT: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Twist Bioscience|TXG (10x Genomics) - Company Value to Revenue|Intellia Therapeutics, Inc. (NTLA) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Stoke Therapeutics Inc|BLFS: Business Value to Revenue|Company Value to Revenue WVE (Wave Life Sciences Corp)|Total Company Value-to-Revenue Ratio Maze Therapeutics Corp|Sionna Therapeutics Inc - Company Value to Revenue|PRME (primemedicine.com) - Enterprise Value to Sales Volume|TSHA - Enterprise Value-to-Revenue Ratio|QURE (uniQure) - Company Value to Revenue Ratio|MeiraGTx Corp (MGTX) - Enterprise Value-to-Revenue Ratio|Regenxbio - Business Value to Revenue|Enterprise Value-to-Revenue Ratio solidbio.com|Enterprise Value-to-Revenue Multiple ocugen.com OCGN|EV/Sales Multiple PACB|Benitec - Company Value to Revenue Ratio|Enterprise Value-to-Revenue Ratio Design Therapeutics DSGN|EV/Sales Multiple Rocket Pharmaceuticals RCKT|Enterprise Value to Sales Volume 4D Molecular Corp|LXEO: Enterprise Value-to-Revenue Ratio|KRRO (Korro Bio, Inc) - Company Value to Revenue|Editas Medicine (EDIT) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Silence Therapeutics Inc.|Company Value to Revenue Ratio PRQR (proqr.com)|Enterprise Value-to-Revenue Ratio Codexis Bio (CDXS)|EV/Sales Multiple sangamo.com (SGMO)|Enterprise Value-to-Revenue Ratio nautilus.bio NAUT|Total Company Value-to-Revenue Ratio Metagenomi, Inc (MGX)|Precision BioSciences Inc. - EV/Sales Multiple|GBIO - EV/Sales Multiple|BOLD: EV/Sales Multiple|Company Value to Revenue Ratio XCUR|Enterprise Value-to-Revenue Ratio Imunon|Phio Pharmaceuticals - Enterprise Value to Sales Volume|Enterprise Value-to-Revenue Ratio Mustang Bio, Inc. (MBIO)|Total Company Value-to-Revenue Ratio TransCode Therapeutics, Inc.|Enterprise Value-to-Revenue Ratio Bionano Genomics BNGO|Business Value to Revenue APDN|BLUE - Enterprise Value-to-Revenue Ratio|Enterprise Value to Sales Volume IPA|Omega Therapeutics, Inc. (OMGA) - Enterprise Value-to-Revenue Ratio|Singular Genomics Corp (OMIC) - EV/Sales Multiple|RGLS (Regulus Therapeutics, Inc.) - EV/Sales Multiple|SYRS: Business Value to Revenue|Company Value to Revenue TBIO (Telesis Bio Inc.)|UBX - Enterprise Value-to-Revenue Multiple